The study, published March 26 in Nature, analyzed studies from 2016 to 2022 to assess the effects of fixed-dose combination therapy, or polypill therapy, to prevent atherosclerotic cardiovascular disease. The trials selected used at least one blood pressure-lowering drug and one lipid-lowering drug.
Among 26 trials, polypills were associated with lower low-density lipoprotein cholesterol and systolic blood pressure, higher rates of adherence, and with adverse events in both primary and mixed secondary prevention populations.
“These findings support adoption and implementation of polypills to lower risk for all-cause mortality and atherosclerotic cardiovascular disease,” the study authors wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
